LAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Standard BioTools Inc (LAB) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The company's financial performance is weak, with a significant drop in net income and EPS. Technical indicators are mixed, and there are no strong positive catalysts or trading signals to justify immediate action. It is better to hold off on investing in this stock for now.
The MACD is positive and expanding, indicating a potential upward momentum. However, the RSI is neutral at 50.874, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 0.924, with resistance at 0.97 and support at 0.878. Overall, the technical indicators do not strongly support a buy decision.
The MACD histogram is positive and expanding, and there is a 70% chance of a modest price increase in the next day, week, and month.
The company's financial performance is poor, with a significant drop in net income (-156.59% YoY) and EPS (-155.56% YoY). Gross margin has also declined. There are no recent news catalysts, analyst ratings, or significant trading trends from hedge funds or insiders. Additionally, no congress trading data is available.
In 2025/Q4, revenue remained flat YoY at $23.795M. However, net income dropped significantly by -156.59% YoY to $19.283M, and EPS fell by -155.56% YoY to 0.05. Gross margin also declined by -3.02% YoY to 47.83%. The financials indicate a deteriorating performance.
No recent analyst ratings or price target changes are available for this stock.
